Cabazitaxel (Synonyms: XRP6258; RPR-116258A; taxoid XRP6258)

Name: Cabazitaxel
Brand: MedChemExpress
SKU: HY-15459
Rating: 5.0 (19 reviews)

Cat. No.: HY-15459 Purity: 99.91%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

For research use only. We do not sell to patients.

Cabazitaxel Chemical Structure

CAS No. : 183133-96-2

Size	Price	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	USD 61	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	USD 61	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	USD 35	In-stock	Estimated Time of Arrival: December 31
10 mg	USD 55	In-stock	Estimated Time of Arrival: December 31
50 mg	USD 88	In-stock	Estimated Time of Arrival: December 31
100 mg	USD 165	In-stock	Estimated Time of Arrival: December 31
500 mg	USD 495	In-stock	Estimated Time of Arrival: December 31
1 g		Get quote
5 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 19 publication(s) in Google Scholar

Other Forms of Cabazitaxel:

17 Publications Citing Use of MCE Cabazitaxel

: Cabazitaxel purchased from MedChemExpress. Usage Cited in: Prostate. 2018 Feb;78(3):166-177. [Abstract]; Western blot analysis of apoptosis marker PARP in stable cell lines treated with 50 or 100 nM Cabazitaxel.

: Cabazitaxel purchased from MedChemExpress. Usage Cited in: Oncotarget. 2016 May 17;7(20):28891-902. [Abstract]; Western blot analyses for Brachyury and AR expression in prostate cell lines treated with Docetaxel (Doc) or with Cabazitaxel (Cab). Graphs represent the densimetric semi-quantification of western blot images.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

Cabazitaxel is a semi-synthetic derivative of the natural taxoid 10-deacetylbaccatin III with potential antineoplastic activity.

Cellular Effect

Cell Line	Type	Value	Description	References
A-431	GI₅₀	1.483 nM Compound: 3	Growth inhibition of human A431 cells by MTT assay Growth inhibition of human A431 cells by MTT assay	[PMID: 24405702]
A549	GI₅₀	1.483 nM Compound: 3	Growth inhibition of human A549 cells by MTT assay Growth inhibition of human A549 cells by MTT assay	[PMID: 24405702]
A549	IC₅₀	15 nM Compound: Cabazitaxel	Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
A549/TR	IC₅₀	62.5 nM Compound: Cabazitaxel	Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human A549/Taxol cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
BGC-823	GI₅₀	467.2 nM Compound: 3	Growth inhibition of human BGC823 cells by MTT assay Growth inhibition of human BGC823 cells by MTT assay	[PMID: 24405702]
DU-145	GI₅₀	1.429 nM Compound: 3	Growth inhibition of human DU145 cells by MTT assay Growth inhibition of human DU145 cells by MTT assay	[PMID: 24405702]
HeLa	GI₅₀	1.799 nM Compound: 3	Growth inhibition of human HeLa cells by MTT assay Growth inhibition of human HeLa cells by MTT assay	[PMID: 24405702]
HL-60	GI₅₀	4.736 nM Compound: 3	Growth inhibition of human HL60 cells by MTT assay Growth inhibition of human HL60 cells by MTT assay	[PMID: 24405702]
HT-1080	GI₅₀	1.406 nM Compound: 3	Growth inhibition of human HT1080 cells by MTT assay Growth inhibition of human HT1080 cells by MTT assay	[PMID: 24405702]
K562	GI₅₀	4.186 nM Compound: 3	Growth inhibition of human K562 cells by MTT assay Growth inhibition of human K562 cells by MTT assay	[PMID: 24405702]
KB	IC₅₀	20 nM Compound: Cabazitaxel	Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay Cytotoxicity against human KB cells assessed as inhibition of cell growth measured after 72 hrs by CCK-8 assay	[PMID: 34058663]
MCF7	GI₅₀	1.187 nM Compound: 3	Growth inhibition of human MCF7 cells by MTT assay Growth inhibition of human MCF7 cells by MTT assay	[PMID: 24405702]
MES-SA/Dx5	IC₅₀	15 nM Compound: Cabazitaxel	Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay Growth inhibition of human MES-SA/Dx5 cells after 72 hrs by SRB assay	[PMID: 29251920]
NCI-H524	IC₅₀	0.26 nM Compound: Cabazitaxel	Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay Cytotoxicity in human NCI-H524 cells pre-incubated for 2 hrs followed by compound wash out and subsequently incubated for 70 hrs by Cell Titer Glo assay	[PMID: 30735385]
PANC-1	GI₅₀	1.283 nM Compound: 3	Growth inhibition of human PANC1 cells by MTT assay Growth inhibition of human PANC1 cells by MTT assay	[PMID: 24405702]
SGC-7901	GI₅₀	0.3553 nM Compound: 3	Growth inhibition of human SGC7901 cells by MTT assay Growth inhibition of human SGC7901 cells by MTT assay	[PMID: 24405702]
U-937	GI₅₀	0.5391 nM Compound: 3	Growth inhibition of human U937 cells by MTT assay Growth inhibition of human U937 cells by MTT assay	[PMID: 24405702]

In Vitro

The cytotoxicity of cabazitaxel (100 μg/mL) on 4T1 cells without irradiation is 70.8%. Cabazitaxel (100 μg/mL) exhibits a concentration-dependent antiproliferation effect, with the antiproliferative activity of 56.2%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Cabazitaxel (10 mg/kg, i.v.) has certain toxicity to liver and kidney but it can be avoided by integrated into Ans. The body weights of mice treated with AN-ICG-CBX and AN-CBX have a slightly decrease, while body weights of the free CBX group significantly decrease compared to the control group^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

Molecular Weight

835.93

Formula

C₄₅H₅₇NO₁₄

CAS No.

183133-96-2

Appearance

Solid

Color

White to off-white

SMILES

CC1=C([C@@H](OC)C([C@@]2(C)[C@@]3([H])[C@](OC(C)=O)(CO4)[C@H]4C[C@@H]2OC)=O)C(C)(C)[C@@]([C@H]3OC(C5=CC=CC=C5)=O)(O)C[C@@H]1OC([C@H](O)[C@H](C6=CC=CC=C6)NC(OC(C)(C)C)=O)=O

Structure Classification

Others

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (119.63 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.1963 mL	5.9814 mL	11.9627 mL
5 mM	0.2393 mL	1.1963 mL	2.3925 mL
10 mM	0.1196 mL	0.5981 mL	1.1963 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (2.99 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.96%

Select Batch:

Data Sheet (286 KB) SDS (557 KB)

COA (263 KB) HNMR (205 KB) RP-HPLC (194 KB) LCMS (140 KB)

Handling Instructions (2659 KB)

References

[1]. Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. [Content Brief]

[2]. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. [Content Brief]

Cell Assay ^[1]	The cytotoxicity of CBX-loaded ANs and free Cabazitaxel (CBX) is evaluated with MTT assay. Cells are seeded onto a 96-well plate at a density of 3000 cells per well and cultured for 24 h. CBX-loaded ANs and free CBX are diluted to predetermined concentrations with PBS and added into each well. Blank AN, AN-ICG and free CBX solvent (a mixture of Tween-80 and anhydrous alcohol) are added as well to different final concentrations. The incubation continued for another 48 hours. 20 µL MTT solutions (5 mg/mL in PBS) are added into each well and cells are incubated for another 4 hours under 37°C. Subsequently the medium is removed and 150 µL dimethyl sulphoxide (DMSO) is added to dissolve the purple formazan salt crystals. Then the absorbance is measured by a microplate reader at 490 nm. The cells treated with medium are evaluated as controls. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[1]	To evaluate the antitumor efficiency of the combined chemotherapy and PTT in vivo, mice bearing 4T1 tumor are randomLy divided into 6 treatment groups (n=5). Treatment begin when the tumors reached 50 mm³-100 mm³. The mice are intravenously injected with saline, AN-ICG, free Cabazitaxel (CBX), AN-CBX and AN-ICG-CBX (ICG 2 mg/kg, CBX 10 mg/kg). 8 hours later, the groups injected with AN-ICG and AN-ICG-CBX is irradiated by the 808 nm laser (0.8 W/cm², 5 min). The length and width of every tumor are measured by a caliper every other day. The formula (volume (mm³) =1/2 × length × width²) is used to calculate the tumor volume. The body weights of these mice are recorded every two days using an electronic balance as well. At the end of the antitumor study, the 4T1 tumor bearing mice are sacrificed to collect the tumors and major organs. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Tai X, et al. Cabazitaxel and indocyanine green co-delivery tumor-targeting nanoparticle for improved antitumor efficacy and minimized drug toxicity. J Drug Target. 2016 Sep 9:1-29. [Content Brief] [2]. Gdowski AS, et al. Bone-targeted cabazitaxel nanoparticles for metastatic prostate cancer skeletal lesions and pain. Nanomedicine (Lond). 2017 Sep;12(17):2083-2095. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.1963 mL	5.9814 mL	11.9627 mL	29.9068 mL
	5 mM	0.2393 mL	1.1963 mL	2.3925 mL	5.9814 mL
	10 mM	0.1196 mL	0.5981 mL	1.1963 mL	2.9907 mL
	15 mM	0.0798 mL	0.3988 mL	0.7975 mL	1.9938 mL
	20 mM	0.0598 mL	0.2991 mL	0.5981 mL	1.4953 mL
	25 mM	0.0479 mL	0.2393 mL	0.4785 mL	1.1963 mL
	30 mM	0.0399 mL	0.1994 mL	0.3988 mL	0.9969 mL
	40 mM	0.0299 mL	0.1495 mL	0.2991 mL	0.7477 mL
	50 mM	0.0239 mL	0.1196 mL	0.2393 mL	0.5981 mL
	60 mM	0.0199 mL	0.0997 mL	0.1994 mL	0.4984 mL
	80 mM	0.0150 mL	0.0748 mL	0.1495 mL	0.3738 mL
	100 mM	0.0120 mL	0.0598 mL	0.1196 mL	0.2991 mL

Cabazitaxel Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cabazitaxel183133-96-2XRP6258 RPR-116258A taxoid XRP6258XRP 6258XRP-6258taxoid XRP6258taxoid XRP 6258taxoid XRP-6258Microtubule/TubulinAutophagyInhibitorinhibitorinhibit

Please select a local distributor ナミキ商事株式会社コスモ・バイオ株式会社
Product Name			Salutation
Applicant Name *			Email Address *
Phone Number *			Organization Name *
Department *			Requested quantity *
Country or Region *
Remarks

Product Name			Lot #
Applicant Name *			Email Address *
Phone Number			Department *
Organization Name *			Country or Region *
Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Cabazitaxel (Synonyms: XRP6258; RPR-116258A; taxoid XRP6258)

Customer Review

Other Forms of Cabazitaxel:

Cabazitaxel Related Antibodies

17 Publications Citing Use of MCE Cabazitaxel

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

Cabazitaxel Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Cabazitaxel Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report